Arkuda Therapeutics

Arkuda Therapeutics, Inc. was a privately held, preclinical-stage biotechnology company based in Watertown, Massachusetts, founded in 2018 by Gerhard Koenig, Ph.D. and Duane Burnett to develop small-molecule enhancers of lysosomal function for neurodegenerative disease. Its lead biology targeted progranulin (GRN) and lysosomal dysfunction in frontotemporal dementia (FTD-GRN), Alzheimer's disease and Parkinson's disease. Arkuda closed a $44M Series A in November 2019 and a $64M Series B in February 2022, backed by Atlas Venture, Cormorant Asset Management, Pfizer Ventures, abrdn plc, Mission BioCapital and Eli Lilly and Company. On 27 February 2024 it entered an option and asset purchase agreement with Johnson & Johnson, and on 9 January 2025 Johnson & Johnson (through Janssen Pharmaceuticals) exercised that option and acquired the entire portfolio of lysosomal function enhancers. Independent operations concluded thereafter; founder and CEO Gerhard Koenig became CEO of Augustine Therapeutics in January 2025. Arkuda was a therapeutics developer, not a software company: it never operated a developer program, public API, SDK or machine-readable API contract, and both of its former domains have since lapsed.

Arkuda Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.

🌐 Visit website 📡 Source on GitHub

3.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesDrug DiscoveryNeurodegenerative DiseaseTherapeuticsAcquired

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 3.9/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 3.9 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/arkuda-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 4

The organization behind the API

LinkedIn

Press

Press

Press

Press

Investor

Investor

Other 1

Properties that don't map to a standard resource type

Archive

Source (apis.yml)

aid: arkuda-therapeutics
name: Arkuda Therapeutics
description: 'Arkuda Therapeutics, Inc. was a privately held, preclinical-stage biotechnology company based in Watertown,
  Massachusetts, founded in 2018 by Gerhard Koenig, Ph.D. and Duane Burnett to develop small-molecule enhancers of lysosomal
  function for neurodegenerative disease. Its lead biology targeted progranulin (GRN) and lysosomal dysfunction in frontotemporal
  dementia (FTD-GRN), Alzheimer''s disease and Parkinson''s disease. Arkuda closed a $44M Series A in November 2019 and a
  $64M Series B in February 2022, backed by Atlas Venture, Cormorant Asset Management, Pfizer Ventures, abrdn plc, Mission
  BioCapital and Eli Lilly and Company. On 27 February 2024 it entered an option and asset purchase agreement with Johnson
  & Johnson, and on 9 January 2025 Johnson & Johnson (through Janssen Pharmaceuticals) exercised that option and acquired
  the entire portfolio of lysosomal function enhancers. Independent operations concluded thereafter; founder and CEO Gerhard
  Koenig became CEO of Augustine Therapeutics in January 2025. Arkuda was a therapeutics developer, not a software company:
  it never operated a developer program, public API, SDK or machine-readable API contract, and both of its former domains
  have since lapsed.'
url: https://raw.githubusercontent.com/api-evangelist/arkuda-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Neurodegenerative Disease
- Therapeutics
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Archive
  name: Arkuda Therapeutics website (archived 2025-03-27)
  url: https://web.archive.org/web/20250327032458/http://arkudatx.com/
- type: LinkedIn
  url: https://www.linkedin.com/company/arkudatx
- type: Press
  name: Johnson & Johnson exercises option and acquires Arkuda portfolio (2025-01-09)
  url: https://www.prnewswire.com/news-releases/arkuda-therapeutics-announces-option-exercise-and-asset-purchase-302346524.html
- type: Press
  name: Johnson & Johnson Innovation — option and asset purchase agreement
  url: https://jnjinnovation.com/news/press-releases/arkuda-therapeutics-announces-option-and-asset-purchase
- type: Investor
  name: Atlas Venture portfolio profile
  url: https://atlasventure.com/company/arkuda-therapeutics/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 0
  pass: local-v1
x-coverage:
  state: none
  reason: defunct
  detail: Arkuda's portfolio was acquired by Johnson & Johnson on 2025-01-09 and independent operations ended; its former
    domain arkudatx.com now serves an Azerbaijani gambling SEO page canonicalized to sapporosushikingston.com, and arkudatherapeutics.com
    is a GoDaddy parking lander that soft-404s every path with byte-identical HTML.
  evidence:
  - url: https://arkudatx.com/
    status: 200
  - url: https://arkudatherapeutics.com/.well-known/agent-card.json
    status: 200
  - url: https://arkudatx.com/openapi.json
    status: 404
  - url: https://web.archive.org/web/20250327032458/http://arkudatx.com/
    status: 200
  checked: '2026-08-06'